Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.
about
Vaccines for Emerging Infectious Diseases: lessons from MERS coronavirus and Zika virus.Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors.Monoclonal antibodies against Zika virus: Therapeutics and their implications for vaccine design.Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction.Recent advances in understanding the adaptive immune response to Zika virus and the effect of previous flavivirus exposure.Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design.Adjuvant-Mediated Epitope Specificity and Enhanced Neutralizing Activity of Antibodies Targeting Dengue Virus Envelope ProteinHuman antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection.Zika virus: what we need to know?Zika Virus: An Emerging Global Health Threat.Development of envelope protein antigens to serologically differentiate Zika from dengue virus infection.Passive immunotherapy of viral infections: 'super-antibodies' enter the fray.Immune Response to Dengue and Zika.Development of Antibody Therapeutics against Flaviviruses.The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design.Humoral Immune Responses Against Zika Virus Infection and the Importance of Preexisting Flavivirus Immunity.Redefining priorities towards graded travel-related infectious disease research.What Is a Host? Attributes of Individual Susceptibility.The immunology of Zika Virus.Immune Responses to Dengue and Zika Viruses-Guidance for T Cell Vaccine Development.Rational Engineering and Characterization of an mAb that Neutralizes Zika Virus by Targeting a Mutationally Constrained Quaternary Epitope.Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection.Longitudinal Analysis of Antibody Cross-Neutralization Following Zika and Dengue Virus Infection in Asia and the Americas.Mouse and Human Monoclonal Antibodies Protect against Infection by Multiple Genotypes of Japanese Encephalitis Virus.Zika convalescent macaques display delayed induction of anmanestic cross-neutralizing antibody responses after dengue infection.Incorporation of NS1 and prM/M are important to confer effective protection of adenovirus-vectored Zika virus vaccine carrying E proteinCritical role of CD4 T cells and IFNγ signaling in antibody-mediated resistance to Zika virus infectionComplementary Mechanisms Potentially Involved in the Pathology of Zika VirusHuman antibodies targeting Zika virus NS1 provide protection against disease in a mouse modelCD4+T cells mediate protection against Zika associated severe disease in a mouse model of infectionImproved Immune Responses Against Zika Virus After Sequential Dengue and Zika Virus Infection in Humans
P2860
Q38156536-BD949CE6-1BF8-4829-A4D0-C74B1AD8B718Q38156674-6D0CF3E6-C741-4516-9ECC-3B2655FDE96FQ38157121-446F7913-4119-4C36-8B95-594567772BE8Q38158099-82E1F8F4-5DEA-430C-B7EC-1DAE92FA534EQ38158407-C6F3AA15-3AFA-486B-A28E-54AEB68235B5Q40043685-E3229AE2-D716-4CDE-B183-564BDBF01402Q41921198-B43059AD-3C75-4F1F-9CC0-376B606CC1E4Q41929032-2770F6EC-F633-4839-8F51-BB9FA6D54125Q44169814-A9528153-021B-4A48-92CC-1CE1B6C5B9FAQ47130545-04ED2233-18ED-426E-96D8-ED1C640F7056Q47269331-830A2B63-4B35-4981-B80C-7FC3A8EF3EDEQ47548101-72E28222-A3B1-46C6-B2DC-E6A5570E416DQ47551925-999EFA52-281C-4EA5-B8CE-AB45D7DED993Q47558158-A98F78D7-61E5-4E5A-BE37-E9BBDF818FE9Q47558217-ED31CE9D-A21B-4634-A86B-F632AE5E127FQ47558315-76F73DF1-A54E-48CA-AF65-DF07A22BCF2CQ47681827-93C6AFF2-878B-4B43-9068-F673EC443B61Q48101193-9B8DEDDB-F545-4688-B257-F4EF0F67DCFEQ51336389-4DBD964F-2A0D-4037-83F2-9E31D889FD4DQ51336680-E8A63802-960B-43F4-9B71-69CB03BE0EFCQ54215484-57828A26-488A-4839-82DD-2138D74E13C5Q54217627-936C6BF6-8ECC-4CAB-98E8-D87F71F363D1Q54241921-C4AEC67A-FD63-4D21-B4C7-BB9D7FD450C8Q54265465-ED2908A5-69F3-493A-8742-17DB8FC7AB19Q55645060-4084E47D-4543-4185-B979-D2FCD8F42B6CQ56000963-A221FBEE-E94F-41AC-9AAB-C727124093BCQ56341683-C0F734D6-C371-4A49-9BFA-2D6B5871D269Q58122069-5E3E62A4-AC85-48C9-8D45-16D9FD9AB41BQ58569620-65257B4C-0789-4708-87A4-A053A33021B4Q58744078-34B1777C-3900-4221-93EC-45AF7D17FF45Q58758276-F80E8FE6-046A-4118-A77C-288070AAD5DE
P2860
Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.
@ast
Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.
@en
type
label
Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.
@ast
Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.
@en
altLabel
Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico
@en
prefLabel
Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.
@ast
Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.
@en
P2093
P2860
P50
P921
P1433
P1476
Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.
@en
P2093
Anna Gazumyan
Anthony P West
Antonio R P de Almeida
Arlene Hurley
Charles M Rice
Cibele Orge
Daniel M Weinberger
Dennis Schaefer-Babajew
Edgar E Sevilla-Reyes
Federico Costa
P2860
P304
597-609.e11
P356
10.1016/J.CELL.2017.04.024
P407
P50
P577
2017-05-01T00:00:00Z